Skip to main content
PMC home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 2001 Aug;38(8):508–514. doi: 10.1136/jmg.38.8.508

VHL c.505 T>C mutation confers a high age related penetrance but no increased overall mortality

B Bender 1, C Eng 1, M Olschewski 1, D Berger 1, J Laubenberger 1, C Altehofer 1, G Kirste 1, M Orszagh 1, V van Velthoven 1, H Miosczka 1, D Schmidt 1, H Neumann 1
PMCID: PMC1734919  PMID: 11483638

Abstract

BACKGROUND—Germline mutations of the VHL gene cause von Hippel-Lindau syndrome (VHL). In southern Germany, a specific mutation in this gene, c.505 T>C, is one of the most frequent alterations owing to a founder effect.
METHODS—This study was conducted to evaluate morbidity, specific clinical risk profile, and mortality among a series of VHL c.505 T/C mutation carriers. A total of 125 eligible subjects carrying VHL c.505 T/C underwent ophthalmoscopy and gadolinium enhanced magnetic resonance imaging of the brain, the spinal cord, and the abdomen. Age related penetrance, morbidity, and mortality were assessed.
RESULTS—Frequently observed lesions were phaeochromocytoma (47%), retinal angiomas (36%), haemangioblastoma of the spine (36%), and haemangioblastoma of the brain (16%). Four patients developed renal cell carcinoma. VHL was symptomatic in 47% of subjects; 30% were asymptomatic despite the presence of at least one VHL related tumour and 23% of the carriers had no detectable VHL lesion. Of the 19 patients who had died (15%), 10 died of symptomatic VHL lesions. Overall penetrance by cumulative incidence functions is estimated at 48% by 35 years and 88% by 70 years. In contrast to the only existing published report based on patients with presumably unselected VHL germline mutations, the mortality rate for c.505 T/C mutation carriers is comparable to that of the general population of Germany.
CONCLUSIONS—Our results are an important example that a specific genotype, at least in the case of VHL c.505 T/C, can favourably impact on mortality despite a high age related penetrance. Our study also indirectly provides objective data which might be useful to the life and health insurance industry; it would appear that c.505 T>C mutation positive subjects have similar disease specific mortality to that of the general population owing to a combination of phenotype and timely detection of mutation carrier status followed by aggressive clinical screening and, if necessary, treatment.


Keywords: VHL gene; c.505 T/C germline mutation; VHL morbidity; VHL mortality

Full Text

The Full Text of this article is available as a PDF (189.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antonarakis S. E. Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat. 1998;11(1):1–3. doi: 10.1002/(SICI)1098-1004(1998)11:1<1::AID-HUMU1>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]
  2. Binkovitz L. A., Johnson C. D., Stephens D. H. Islet cell tumors in von Hippel-Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasias. AJR Am J Roentgenol. 1990 Sep;155(3):501–505. doi: 10.2214/ajr.155.3.1974734. [DOI] [PubMed] [Google Scholar]
  3. Brauch H., Kishida T., Glavac D., Chen F., Pausch F., Höfler H., Latif F., Lerman M. I., Zbar B., Neumann H. P. Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum Genet. 1995 May;95(5):551–556. doi: 10.1007/BF00223868. [DOI] [PubMed] [Google Scholar]
  4. Cendron M., Wein A. J., Schwartz S. S., Murtagh F., Livolsi V. A., Tomaszewski J. E. Germ cell tumor of testis in a patient with von Hippel-Lindau disease. Urology. 1991 Jan;37(1):69–71. doi: 10.1016/0090-4295(91)80082-i. [DOI] [PubMed] [Google Scholar]
  5. Choyke P. L., Glenn G. M., Walther M. M., Patronas N. J., Linehan W. M., Zbar B. von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology. 1995 Mar;194(3):629–642. doi: 10.1148/radiology.194.3.7862955. [DOI] [PubMed] [Google Scholar]
  6. Crossey P. A., Richards F. M., Foster K., Green J. S., Prowse A., Latif F., Lerman M. I., Zbar B., Affara N. A., Ferguson-Smith M. A. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet. 1994 Aug;3(8):1303–1308. doi: 10.1093/hmg/3.8.1303. [DOI] [PubMed] [Google Scholar]
  7. Fill W. L., Lamiell J. M., Polk N. O. The radiographic manifestations of von Hippel-Lindau disease. Radiology. 1979 Nov;133(2):289–295. doi: 10.1148/133.2.289. [DOI] [PubMed] [Google Scholar]
  8. Glenn G. M., Daniel L. N., Choyke P., Linehan W. M., Oldfield E., Gorin M. B., Hosoe S., Latif F., Weiss G., Walther M. Von Hippel-Lindau (VHL) disease: distinct phenotypes suggest more than one mutant allele at the VHL locus. Hum Genet. 1991 Jun;87(2):207–210. doi: 10.1007/BF00204184. [DOI] [PubMed] [Google Scholar]
  9. Harries R. W. A rational approach to radiological screening in von Hippel-Lindau disease. J Med Screen. 1994 Apr;1(2):88–95. doi: 10.1177/096914139400100205. [DOI] [PubMed] [Google Scholar]
  10. Horton W. A., Wong V., Eldridge R. Von Hippel-Lindau disease: clinical and pathological manifestations in nine families with 50 affected members. Arch Intern Med. 1976 Jul;136(7):769–777. doi: 10.1001/archinte.136.7.769. [DOI] [PubMed] [Google Scholar]
  11. Lamiell J. M., Salazar F. G., Hsia Y. E. von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore) 1989 Jan;68(1):1–29. doi: 10.1097/00005792-198901000-00001. [DOI] [PubMed] [Google Scholar]
  12. Levine E., Weigel J. W., Collins D. L. Diagnosis and management of asymptomatic renal cell carcinomas in von Hippel-Lindau syndrome. Urology. 1983 Feb;21(2):146–150. doi: 10.1016/0090-4295(83)90010-9. [DOI] [PubMed] [Google Scholar]
  13. MELMON K. L., ROSEN S. W. LINDAU'S DISEASE. REVIEW OF THE LITERATURE AND STUDY OF A LARGE KINDRED. Am J Med. 1964 Apr;36:595–617. doi: 10.1016/0002-9343(64)90107-x. [DOI] [PubMed] [Google Scholar]
  14. Maher E. R., Kaelin W. G., Jr von Hippel-Lindau disease. Medicine (Baltimore) 1997 Nov;76(6):381–391. doi: 10.1097/00005792-199711000-00001. [DOI] [PubMed] [Google Scholar]
  15. Maher E. R., Webster A. R., Richards F. M., Green J. S., Crossey P. A., Payne S. J., Moore A. T. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet. 1996 Apr;33(4):328–332. doi: 10.1136/jmg.33.4.328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Maher E. R., Yates J. R., Harries R., Benjamin C., Harris R., Moore A. T., Ferguson-Smith M. A. Clinical features and natural history of von Hippel-Lindau disease. Q J Med. 1990 Nov;77(283):1151–1163. doi: 10.1093/qjmed/77.2.1151. [DOI] [PubMed] [Google Scholar]
  17. Malek R. S., Omess P. J., Benson R. C., Jr, Zincke H. Renal cell carcinoma in von Hippel-Lindau syndrome. Am J Med. 1987 Feb;82(2):236–238. doi: 10.1016/0002-9343(87)90062-3. [DOI] [PubMed] [Google Scholar]
  18. Neumann H. P., Lips C. J., Hsia Y. E., Zbar B. Von Hippel-Lindau syndrome. Brain Pathol. 1995 Apr;5(2):181–193. doi: 10.1111/j.1750-3639.1995.tb00592.x. [DOI] [PubMed] [Google Scholar]
  19. Neumann H. P., Wiestler O. D. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet. 1991 May 4;337(8749):1052–1054. doi: 10.1016/0140-6736(91)91705-y. [DOI] [PubMed] [Google Scholar]
  20. Neumann H. P., Zbar B. Renal cysts, renal cancer and von Hippel-Lindau disease. Kidney Int. 1997 Jan;51(1):16–26. doi: 10.1038/ki.1997.3. [DOI] [PubMed] [Google Scholar]
  21. Zbar B., Kishida T., Chen F., Schmidt L., Maher E. R., Richards F. M., Crossey P. A., Webster A. R., Affara N. A., Ferguson-Smith M. A. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat. 1996;8(4):348–357. doi: 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES